一、项目建设地点：
I. Project Location
丹江口经济开发区水都工业园
Shuidu Industrial Park, Danjiangkou Economic Development Zone
二、项目建设背景及市场预测
II. Project Construction Background and Market Forecast
1、项目背景
1. Project background
目前我市已培育一批生物医药企业。从事激素原料药中间体生产企业3家，具备年产1000多吨甾体激素原料药中间体生产能力。
At present, our city has cultivated a number of bio-pharmaceutical enterprises. There are three manufacturing enterprises engaged in hormone API intermediates, with an annual output of more than 1,000 tons of steroid hormone API intermediates.
2、市场预测
2. Market forecast
甾体激素具有极重要的医药价值，在维持生命、调节性功能、机体发展、免疫调节、皮肤疾病治疗及生育控制方面有明确的作用。国外已经上市的甾体和激素类药物有400多种，但在我国现有品种占有率较低，离世界先进水平还有很大的距离，甾体和激素类药物还有很大的发展空间。目前我市现有医药企业在研发水平和实力上的主要差距在产品的开发和市场开拓方面，本项目的建立将改变这一格局，着重产品的开发和市场的开拓，推进甾体和激素药物的研发，产业化和市场化。
Steroid hormones have extremely important medicinal values and have clear roles in life maintenance, regulation of sexual function, organism development, immune regulation, skin disease treatment, and fertility control. There are more than 400 kinds of steroid and hormone drugs that have been marketed abroad, but in China, the occupancy rate of the existing varieties is low, and there is still a great distance from the international advanced level. Steroid and hormone drugs still have a lot of room for development. At present, the main gap between the existing pharmaceutical enterprises in our city in terms of R&D level and strength lies in the development of products and market exploitation. The establishment of the project will change the very pattern, focusing on product development and market exploitation to promote R&D, industrialization, and marketing of steroid and hormone drugs.
三、项目建设的必要性
III. Necessity of Project Construction
目前，国家已把甾体激素药物新资源开发作为医药行业近期技术发展的方向和重点之一。我国在甾体药物研究开发方面与世界先进国家相比还有一定的差距，许多甾体药物特别是技术含量高的甾体药物的研究还是空白，急需我们去研究开发。目前我市已加工的甾体激素产业链产品有：皂素、双烯、沃氏氧化物、17a－羟基黄体酮、去氢表雄酮、表雄酮、甲基睾丸素等。存在的主要问题是生产技术含量还较低、产品深加工程度不够，附加值偏低、产业链位置较前。这些产品恰恰是甾体激素药物合成非常宝贵的原料。这些价值较低的原料进一步深加工成甾体药物后可使这些产品的附加值大大提高，对我市医药经济发展十分有益。
At present, China has made the development of new resources for steroid hormone drugs one of the orientations and priorities for the recent technological development of the pharmaceutical industry. For steroid drug R&D, China still lags behind the world's advanced countries, and there are still gaps in the research of many steroid drugs, especially the research of steroid drugs with high technology content, which we urgently need to fill. At present, the city has processed some products in the steroid hormone industry chain, including saponin, diene, 16-17 alpha-Epoxyprogesterone, 17a hydroxyprogesterone, dehydroepiandrosterone, epiandrosterone, and 17-methyltestosterone. The main problems include low production technology, insufficient further processing of products, low added value, and the front position of the industrial chain. These products happen to be very valuable raw materials for steroid hormone drug synthesis. After being further processed into steroid drugs, the added value of these low-value raw materials will be greatly increased, which is very beneficial to the development of the city's pharmaceutical economy.
四、建设规模及投资估算
IV. Construction Scale and Investment Estimate
项目总投资2亿元，新建环丙氯地孕酮醋酸酯及中间体车间、非那雄胺及其中间体车间、醋酸诺孕酮车间、综合办公楼、仓库等。配套建设水、电等公用辅助设施。项目建成投产后将实现年产环丙氯地孕酮醋酸酯（CPA）1000公斤、环丙氯地孕酮醋酸酯中间体14000公斤/年、非那雄胺2100公斤/年、非那雄胺中间体6000公斤/年、醋酸诺孕酮4000公斤/年的目标。
The total investment of the project is RMB 200 million. A new workshop for cyproterone acetate and intermediates, finasteride and its intermediates, and norgestrel acetate production, a comprehensive office building, and a warehouse should be built. Utilities auxiliary facilities should be set up. After the project is completed and put into operation, it will achieve the annual production capacity of 1,000 kg of cyproterone acetate (CPA), 14,000 kg of cyproterone acetate intermediates, 2,100 kg of finasteride, 6,000 kg of finasteride intermediates, and 4,000 kg of norgestrel acetate.
五、效益分析
V. Benefits Analysis
项目建成达产后，预计可实现年销售收入5亿元、正常年销售税金3958万元、正常年销售利润1亿元、动态投资回收期6年。
After the project is completed and reaches target output, it is expected to achieve an annual sales revenue of RMB 500 million, a normal annual sales tax of RMB 39.58 million, and a normal annual sales profit of RMB 100 million. The dynamic investment payback period will be 6 years.
六、合作方式：
VI. Cooperation
企业独资或与本地企业合资
Sole proprietorship or joint venture with local enterprises
七、项目单位及联系方式
VII. Employer and Contact Details
项目单位：丹江口市招商服务中心
Employer: Danjiangkou Investment Promotion Service Center
徐牧 13971933080 0719-5239196
Xu Mu: 13971933080; 0719-5239196
E-mail:djkszsj@163.com
